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Abstract.  The  term  splanchnic  vein  thrombosis  encompasses  Budd
extrahepatic portal vein obstruction (EHPVO), and mesenteric vein thrombosis. 
Risk factors can be local or systemic. A local precipitating factor is rare in BCS, while it is commo
in    patients  with  portal  vein  thrombosis.  Chronic  myeloproliferative  neoplasms  (MPN)  are  the 
leading systemic cause of splanchnic vein thrombosis, and are diagnosed in half BCS patients and 
one-third of EHPVO patients; the 
of  patients  with  overt  MPN, and  up  to  40%  of  patients  without  overt  MPN.  Inherited 
thrombophilia  is  present  in  at  least  one
prothrombin  G20210A  mutations  are  the  most  common  m
patients, respectively. Multiple factors are present in approximately one
and two- thirds of patients with portal vein thrombosis. 
In a few patient series from the Southern Mediterranean area the h
thrombophilia as underlying cause of BCS is confirmed, although the data should be considered 
preliminary.  Peculiar  risk  factors  present  in  the  area  are  Beh
moreover,  membraneous  webs,  typically  found
portion of cases. 
Definition. The portal vein is formed by the union of 
the superior mesenteric and splenic veins. At the porta 
hepatis, the portal vein  divides into the right and left 
branches, which are segmentally distributed throughout 
the  liver;  the  terminal  portal  venules  drain 
sinusoids. The hepatic venous outflow travels through 
the three hepatic veins to the inferior vena cava. The 
term  splanchnic  vein  thrombosis  encompasses 
occlusions of veins that constitute either the portal vein 
system  or  the  hepatic  veins  (Budd-C
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The  term  splanchnic  vein  thrombosis  encompasses  Budd-Chiari  syndrome  (BCS), 
extrahepatic portal vein obstruction (EHPVO), and mesenteric vein thrombosis. 
Risk factors can be local or systemic. A local precipitating factor is rare in BCS, while it is commo
in    patients  with  portal  vein  thrombosis.  Chronic  myeloproliferative  neoplasms  (MPN)  are  the 
leading systemic cause of splanchnic vein thrombosis, and are diagnosed in half BCS patients and 
third of EHPVO patients; the somatic mutation JAK2 V617F is detectable in a large majority 
and  up  to  40%  of  patients  without  overt  MPN.  Inherited 
thrombophilia  is  present  in  at  least  one-third  of  patients,  and  the  factor  V  Leiden  or  the 
prothrombin  G20210A  mutations  are  the  most  common  mutations  found  in  BCS  or  EHPVO 
ultiple factors are present in approximately one-third of patients with BCS 
thirds of patients with portal vein thrombosis. 
In a few patient series from the Southern Mediterranean area the high prevalence of MPN and 
thrombophilia as underlying cause of BCS is confirmed, although the data should be considered 
preliminary.  Peculiar  risk  factors  present  in  the  area  are  Behçet’s  disease  and  hydatidosis; 
moreover,  membraneous  webs,  typically  found in  Asian  patients,  are  present
The portal vein is formed by the union of 
the superior mesenteric and splenic veins. At the porta 
hepatis, the portal vein  divides into the right and left 
branches, which are segmentally distributed throughout 
the  liver;  the  terminal  portal  venules  drain  into  the 
sinusoids. The hepatic venous outflow travels through 
the three hepatic veins to the inferior vena cava. The 
term  splanchnic  vein  thrombosis  encompasses 
occlusions of veins that constitute either the portal vein 
Chiari  syndrome, 
BCS). 
BCS  is  defined as  any  obstruction of  the  hepatic 
venous outflow at any region from the small hepatic 
veins to the junction of the inferior vena cava and the 
right atrium.  The obstruction can involve small hepatic 
veins, large hepatic veins, the inferior vena cava, or a 
combination of these sites. Outflow obstruction can be 
caused  by  hepatic  veno-occlusive  disease  (sinusoidal 
obstruction syndrome) or cardiac disorders associated 
with right heart failure, which are not included in this
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Chiari  syndrome  (BCS), 
extrahepatic portal vein obstruction (EHPVO), and mesenteric vein thrombosis. 
Risk factors can be local or systemic. A local precipitating factor is rare in BCS, while it is common 
in    patients  with  portal  vein  thrombosis.  Chronic  myeloproliferative  neoplasms  (MPN)  are  the 
leading systemic cause of splanchnic vein thrombosis, and are diagnosed in half BCS patients and 
detectable in a large majority 
and  up  to  40%  of  patients  without  overt  MPN.  Inherited 
third  of  patients,  and  the  factor  V  Leiden  or  the 
utations  found  in  BCS  or  EHPVO 
third of patients with BCS 
igh prevalence of MPN and 
thrombophilia as underlying cause of BCS is confirmed, although the data should be considered 
et’s  disease  and  hydatidosis; 
are  present in  a  significant 
BCS  is  defined as  any  obstruction of  the  hepatic 
venous outflow at any region from the small hepatic 
veins to the junction of the inferior vena cava and the 
right atrium.  The obstruction can involve small hepatic 
c veins, the inferior vena cava, or a 
combination of these sites. Outflow obstruction can be 
occlusive  disease  (sinusoidal 
obstruction syndrome) or cardiac disorders associated 
with right heart failure, which are not included in thisMediterr J Hematol Infect Dis 2011; 3: Open Journal System
definition.
1
EHPVO  is  defined  as  obstruction  of  the  extra-
hepatic portal vein. The obstruction may occlude the 
intra-hepatic  portal  veins,  splenic  veins,  or  superior 
mesenteric veins. EHPVO also includes the formation 
of  portal  cavernomas  and  the  development  of  portal 
hypertension,  which  are  associated  with  long-term 
disease. Isolated occlusion of the  splenic or superior 
mesenteric  vein,  as  well  as  portal  vein  obstruction 
associated with chronic liver disease or tumor,  is not 
defined as EHPVO.
2
Epidemiology. 
Budd-Chiari syndrome: The annual incidence of BCS 
is  0.4  to  0.8  per  million  individuals  in  Western 
countries
3-5 and 0.1 per million in Japan.
3 BCS has a 
prevalence of 1.4 per million individuals in Western 
Countries
5 and 2.4 per million in Japan.
3
Extrahepatic portal vein obstruction: In the 1980s, the 
estimated annual incidence of portal vein thrombosis 
was  less  than  4  per  million  individuals;
4 indeed, 
autopsy studies have shown that portal vein thrombosis 
is present in approximately 1% of cases – one-third are 
EHPVO  and  two-thirds  are  related  to  cirrhosis  or 
hepatocarcinoma.
6
Mesenteric vein thrombosis: The annual incidence of 
superior mesenteric vein thrombosis is 2,7 per 100,000 
individuals.
7 Isolated  MVT  without  concomitant 
EHPVO and splenic vein thrombosis is rare.
8,9
Clinical Presentation.
Budd-Chiari  syndrome:  Posthepatic  obstruction 
associated  with  BCS  leads  to  increased  sinusoidal 
pressure, which may cause perisinusoidal necrosis and 
eventually liver failure. Hepatomegaly, splenomegaly, 
right upper abdominal quadrant pain, and ascites occur 
in  the  majority  of  patients.
10,11 Additionally,  portal 
hypertension can develop and EHPVO is concomitant 
in 14% of cases.
10
BCS symptoms depend on the extent and rapidity of 
the  hepatic  outflow  obstruction, as  well  as  liver 
decompression via a collateral blood flow; accordingly, 
disease  presentation  can  be  classified  as  fulminant, 
acute,  subacute  or    chronic.
1 Fulminant  BCS  is  rare 
(5%  of  cases)  and  is  associated  with  a  rapid  onset, 
hepatocellular  necrosis,  and  hepatic  encephalopathy. 
Acute  BCS  is  reported  in  20%  of  patients  and  is 
associated with symptoms that last for a short duration, 
such  as  ascites  and  hepatic  necrosis,  without  the 
formation of venous collaterals. The chronic form of 
BCS  is the most common form as it occurs in 60% of 
cases,  usually with  symptoms  of  portal  hypertension 
and  liver  cirrhosis.
11 The  remaining  15%  of  BCS 
patients are asymptomatic because one patent hepatic 
vein  or  large  collaterals  can  preserve  the  hepatic 
outflow.
12 However, in a recent multicentre survey of 
consecutive  cases,  the  prevalence  of  asymptomatic 
BCS was notably lower (3%), and the mortality rate at 
6 months was 10%.
13 After 10 years of follow-up, the 
overall survival of patients with BCS was 57-62%.
10,14
Extrahepatic  portal  vein  obstruction:  EHPVO 
presentation can be acute or chronic. Acute thrombosis 
is characterized by a sudden onset of abdominal pain, 
no  evidence  of  chronic  portal  hypertension 
(gastrointestinal  bleeding,  ascites,  collateral 
portosystemic  circulation,  or  hypersplenism),  and  no 
imaging  or  ultrasound  evidence  of  portosystemic 
collateral veins. In the absence of an underlying liver 
disease, liver function is normal due to a compensatory 
increase in  the hepatic arterial blood flow, as well as a 
rapid development of collateral veins. If the mesenteric 
veins are also obstructed, there is a substantial risk of 
intestinal  ischemia  and  subsequent  bowel  infarction. 
EHPVO  may  also  be  asymptomatic  and  can  be 
occasionally diagnosed as the chronic form.
15 Chronic 
EHPVO is the late-stage sequela of thrombosis and is 
usually defined by the presence of a portal cavernoma. 
The  disease  is  characterised  by  replacement  of  the 
portal vein by fibrous tissue and the development of 
periportal  collateral  vessels.  Chronic  EHPVO  can 
cause portal hypertension with splenomegaly,  and the 
frequency of bleeding of oesophageal varices is high as 
12% patient-years.
16 Other less frequent manifestations 
of chronic EHPVO include portal cholangiopathy and 
hepatic  encephalopathy.
15 The  overall  survival  of 
patients with EHPVO is 54%  after 10 years, although 
in the absence of cancer, cirrhosis, and thrombosis of 
the mesenteric vein, the survival rate  is increased to 
81%.
17 However,  the  mortality  rate  of  patients  with 
chronic EHPVO and mesenteric vein thrombosis is 5% 
at one year.
17
Mesenteric vein thrombosis: MVT presentation can be 
acute,  subacute,  or  chronic.
18 Acute  thrombosis  is 
associated with a bowel infarction in one-third of the of 
patients,
7 and the mortality rate of MVT is 20%.
7 In the 
vast  majority  of  patients,  the  onset  of  MVT  is 
characterised by acute abdominal pain. Other common 
symptoms  include  diarrhea  ,  nausea,  vomiting,  and 
lower  gastrointestinal  bleeding.
18 MTV  is  associated 
with  EHPVO  in  65%  of    patients,
8 and  chronic 
presentation  with  no  acute  abdominal    pain  and 
extensive venous collateral circulation is common.
18
Risk  factors.  Risk  factors  for  splanchnic  vein 
thrombosis can be local or systemic, and the latter are 
influenced by inherited or acquired conditions (Tables 
1-2). The combination of multiple concurrent factors is 
present  in  10-46%  of  patients  with BCS
13,19-22 and in Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Causes of Budd-Chiari syndrome (BCS) in adults.
LOCAL RISK FACTORS (%) % of the  patients SYSTEMIC RISK FACTORS (%) % of the  
patients
- Acquired - Inherited
Cancer 6-7 Antithrombin deficiency 2-5
Cirrhosis 8-14 Protein C deficiency 2-9
Abdominal infection 7 Protein S deficiency 3-7
Liver abscess 2 Factor V Leiden 4-26
Inflammatory bowel   diseases 3–8 Prothrombin G20210A 3-8
Membranous web 1-4 (West)-30 (East) - Acquired
- Circumstantial Myeloproliferative neoplasms  (MPN) 23-49
Abdominal surgery 2-23 JAK2 V617F (with overt MPN) 57-100
Splenectomy 2 JAK2 V617F (without overt MPN) 44
Abdominal trauma 10 Antiphospholipid antibodies 1-11
Behcet disease 4-9
Autoimmune diseases 10-13
Paroxysmal nocturnal hemoglobinuria  2-19
Hyperhomocysteinemia 2-9
- Circumstantial*
Oral contraceptives 15-50
Hormone replacement therapy 14
Pregnancy or puerperium 4-16
* percentage calculated on the number of women. 
The per cent values are the rate ranges from single studies
5,9,13,19-22,33 and from revision papers.
25,27,28
Table 2. Causes of portal vein thrombosis in adults.
LOCAL RISK FACTORS (%) % of the patients SYSTEMIC RISK FACTORS (%) % of the patients
- Acquired - Inherited
Cancer 13-24 Antithrombin deficiency 1-2
Cirrhosis 17-18 Protein C deficiency 1–9
Abdominal infection 10 Protein S deficiency 1-5
Liver abscess 3–5 Factor V Leiden 3-8
Inflammatory bowel diseases 1-4 Prothrombin G20210A 3-22
Pancreatitis 6-19 - Acquired
Cholecystitis 2-7 Myeloproliferative neoplasms (MPN) 6-33
Appendicitis 1 JAK2 V617F (with overt MPN) 78-100
Tuberculous lymphadenitis 3 JAK2 V617F (without overt MPN) 27
Neonatal omphalitis 1–6 Antiphospholipid antibodies 3-13
- Circumstantial Autoimmune diseases 1-4
Abdominal surgery 10-30 Paroxysmal nocturnal hemoglobinuria  1-2
Splenectomy 7 Hyperhomocysteinemia 9-19
Cholecystectomy 3-12 Increased FVIII levels 60
Gastrectomy 3 - Circumstantial*
Liver transplantation 2 Oral contraceptives 15-30
Abdominal trauma 1– 3 Hormone replacement therapy 3
Pregnancy or puerperium 2-3
* percentage calculated on the number of women. 
The per cent values are the rate ranges from single studies
17,20-23,29 and from revision papers.
25,37,28,30
10-64% of patients with portal vein thrombosis.
17,20-23
BCS is considered primary when obstruction of the 
hepatic  venous  outflow  tract  is  the  result  of  an 
endoluminal  venous  lesion  (thrombosis  or  web).  In 
contrast,  BCS  is  considered  secondary  when  the 
obstruction results from the presence of extravascular 
material (for example a tumor or a parasitic mass) in 
the  lumen  or  from  extrinsic  compression  (such  as 
abscesses, cysts, tumors). Although the presence of a 
membraneous web that obstructs the terminal portion 
of  the  inferior vena cava  is  a  rare  cause  of  BCS  in  
Western countries, it causes a large majority of cases in 
Oriental  countries.
3 There  is  evidence  that  these 
occluding membraneous  webs  are  not  congenital but 
are  the  late-stage  sequelae  of  a  previous  thrombotic 
obstruction of the inferior vena cava.
3
Recent studies from India have shown that isolated 
inferior vena cava obstruction is nowadays diagnosed 
in  a  minority  of  patients.
24 Poverty,  malnutrition, 
recurrent bacterial infections, and filariasis have been 
suggested to be predisposing factors for inferior vena 
cava  occlusion. Thus,  improvements  in  hygienic  and 
sanitary  conditions  in  Eastern  patients  may  partially 
explain the recent change in BCS pathogenesis. 
In  Western  countries,  most  BCS  patients  are 
females, whereas in Asia the male to female ratio is Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
close  to  1.
3 Use  of oral contraceptive is  common  in 
Western  countries  while  it  is  rare  in  the  Eastern 
countries.  A  higher  prevalence  of  pregnancy  or 
puerperium  associated  BCS  is  found  in  Asian 
countries,  as  such  oral contraceptive-related  BCS  is 
more common in Western countries than that in Asia.
The leading cause of splanchnic vein thrombosis is 
myeloproliferative  neoplasms  (MPN),  which  are 
diagnosed  in  half  of  BCS  patients  and  one-third  of 
EHPVO patients.
13,17,20,21,25 Until the mid 1990s, the so-
called  occult  MPN  was  diagnosed  on  the  basis  of 
spontaneous endogenous erythroid colonies (growth of 
erythroid  colonies  in  the  absence  of  exogenous 
erythropoietin),
25 which allowed recognizition of MPN 
in the early stages. However, this positive result did not 
fulfil the complete diagnostic criteria for up to 80% of 
BCS patients and 50% of EHPVO patients.
25 Recently, 
the JAK2 V617F mutation has been reported to be the 
main  molecular  marker  of  the  Philadelphia-negative 
MPN. This mutation occur in nearly all patients with 
polycythemia  vera  and  in  about  half  of  the  patients 
with essential thrombocytemia. Thus, this mutation is 
now  recognised  as  a  diagnostic  cornerstone.
26 The 
close relationship between MPN and splanchnic vein 
thrombosis has been confirmed by the current one-third 
prevalence  of  the  JAK2  V617F  mutation  among 
patients  with  BCS  and  EHPVO  (Tables  1-2).
27,28
Patients with splanchnic vein thrombosis that show no 
additional signs of haematologic disease other than the 
JAK2 V617F mutation at the time of thrombosis have 
an overt MPN development rate as high as 52% during 
the follow-up.
28
Inherited  thrombophilia  is  found  in  patients  with 
splanchnic  vein  thrombosis,  although  diagnosis  of 
inherited deficiencies of antithrombin, protein C, and 
protein  S  is  difficult  in  the  presence  of  liver 
impairment, which causes a reduced synthesis of the 
natural anticoagulant proteins.
13,23,29,30 This difficulty is 
not present with the factor V Leiden and prothrombin 
G20210A mutations. Interestingly,  a  high  prevalence 
of  prothrombin  G20210A  mutation  has  been 
consistently reported in various series of patients with 
EHPVO,
23,29,30 whereas factor V Leiden  appears to be 
more  common  in  BCS  patients.
13,21 A  recent  meta-
analysis  showed  a  4-fold  increased    risk  for 
prothrombin G20210A in EHPVO patients and a 2-fold 
increased risk for factor V Leiden in BCS patients.
30
BCS is the most frequent thrombotic complication 
of paroxysmal nocturnal hemoglobinuria (41% of the 
occlusive events)
31 and of Behcet’s disease (26% of the 
occlusive events).
32
The known circumstantial risk factors for BCS are 
pregnancy,  puerperium  and  the  use  of  oral 
contraceptives.
33,34 A  case  control  study  showed  that 
oral  contraceptives  were  associated  with  a  2.4-fold 
increased  risk  of  BCS,
34 although  a  more  current 
estimation for currently used hormone preparations is 
needed.   
While a local precipitating factor is rare in patients 
with BCS,
19,20,21 it is identified in at least one-third of 
the  patients  with  portal  vein  thrombosis.
15
Inflammatory  or  malignant  abdominal  foci,  surgical 
trauma to the portal vein,  and liver cirrhosis are among 
the local causes of portal vein thrombosis (Table 2). 
EHPVO develops in about 5% of patients undergoing 
splenectomy,  especially  in  patients  with  cancer, 
myeloproliferative  disorders  or  haemolytic  anemia.
35
Reports on the risk factors associated with MVT were 
mostly anedoctal until recently, when an autopsy series 
and  a  population-based  study  were  published.
7,8 The 
autopsy study stated that abdominal cancer was present 
in 22% of cases and liver cirrhosis was present in 17%. 
The  population-based  study  showed  a  marker  of 
thrombophilia  in  67%  of  patients,  a  local  factor 
(surgery or inflammation) in 25%, cancer in 24%, and 
oral contraceptive use  in 6% of patients.
Risk factors in the Southern Mediterranean area: The 
large  majority  of  reports  concerning  BCS  are  from 
Western  countries  or  Asia  (in  particular,  India  and 
Japan).  A  few  case  series  of  adult  patients  from 
countries  of  the  Southern  Mediterranean  area  are 
available. 
In a survey from Israel,
36 29 patients with hepatic 
vein  thrombosis  were  diagnosed  between  1955  and 
1975. Fifteen of the patients were Jews and 14 were 
Arabs. In contrast to the Jewish patients, all of whom 
were  adults,  the  majority  of  the  Arab  patients  were 
children below 10 years of age. Primary hepatic vein 
occlusion was  2.4 times more common  among  Arab 
than among Jewish patients. Of the 11 Arab patients 
with  primary  hepatic  vein  occlusion,  three  had 
histological changes typical of veno-occlusive disease; 
whereas in five others, thrombotic occlusion of large 
hepatic  veins  or  of  the  vena  cava  was  documented. 
Although  no  plant  alkaloids  could  be  directly 
implicated in any of the Arab patients, circumstantial 
evidence strongly supports such an etiology; all Arab 
patients  originated  from  small  agricultural 
communities  where  ancient  methods  of  winnowing, 
which expose the home-ground wheat to a high risk of 
contamination  by  grains  containing  pyrrolizidine 
alkaloids, are still in use. 
In a series of 22 patients with BCS from Israel,
37 10 
demonstrated spontaneous erythroid cell growth (45%), 
in two cases associated with overt polycythemia vera.  
Seven  patients  (32%)  had  protein  C  deficiency,  six 
patients (27%) had activated protein C resistance, five 
(23%) had anti-cardiolipin antibodies, five (23%) had 
antithrombin deficiency, and four patients (18%) had Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
protein S deficiency.
In a series from Saudi Arabia out of 29 patients with 
BCS,
38 nine patients had Behcet's disease (31%); seven 
had  malignancy  (24%),  eight  had  antiphospholipid 
syndrome (27%); of the remaining patients, two had no 
known  cause,  one  had  trauma,  one  had  protein  C 
deficiency,  and one had a  nephrotic syndrome.
In  a  large  series  of  75  patients  with  BCS  from 
Turkey,
39 at least one etiological factor was determined 
in 54 (72%) of them. The etiology could not be defined 
in 21 (28%) patients. One etiological factor was found 
in 52% of patients,  two in 19%, and three factors in 
1%.  The  most  common  acquired  causes  were 
membraneous  webs  in  12  patients,  (16%),    hydatid 
disease in eight (11%), Behcet’s disease in seven (9%). 
Overall,  thrombophilia  (antithrombin,  protein  C, 
protein  S  deficiency,  APC-resistance,  anticardiolipin 
antibodies) was detected in 20 patients (26%). Notably, 
overt MPN were diagnosed only in six patients (8%). 
In  this  series  the  JAK2  V617F  mutation  was  not 
investigated; therefore, the prevalence of MPNs could 
be  underestimated.  BCS  was  associated  with
pregnancy in 14% of 35 female patients and with oral 
contraceptive use in 8%.
In a series of 94 patients with BCS from Egypt
40 at 
least  one  etiological  factor  was  found  in  49%  of 
patients, two in 31%, three in 8%, and four in 3%. The 
JAK2  V617F  mutation  was  found  in  29%  of  62 
patients tested; Behcet’s disease was diagnosed in 12 
patients (13%). Overall, antithrombin, protein C, and 
protein  S  deficiencies  were  found  in  nine  patients 
(9%);  out  of  64  patients  tested,  10    patients  were 
homozygous  for  factor  V  Leiden  and  24  were 
heterozygous  (52%),  whereas  prothrombin  G20210A 
was detectable only in 5%. This exceeding prevalence 
of factor V Leiden could mirror the high prevalence of 
the  mutation  in  the  general  population  of  this 
geographic  area  .
41 A  total  of  15%  of  58  female 
patients had received hormonal treatment whereas 17% 
had BCS associated with pregnancy.
A series of 95 patients with portal vein thrombosis 
(in  25% of cases associated with liver cirrhosis) has 
been  described  in  Turkey;
42 nine patients  had  overt 
MPN  (10%).  The  prevalence  of  inherited 
thrombophilia in this series is not reliable due to the 
lack  of  investigation  for  factor  V  Leiden  and 
prothrombin G20210A.
Conclusions. In the Southern Mediterranean area the 
association of deficiency of natural anticoagulants with 
BCS  is  similar  to  that  found  in  Western  countires; 
unfortunately, the prevalence of factor V Leiden and 
prothrombin G20210A is  described only in one study 
from Egypt, reporting the presence of factor V leiden 
in  half  of the  patients. The  presence of  spontaneous 
endogenous  erythroid  growth  or  JAK2  V617F  as 
reliable signs of MPN has been detected in one-third to 
half of patients, with a prevalence quite similar to that 
reported in patient series from Western countries.
Interestingly,  Behcet’s  disease  is  the  underlying 
cause of BCS in about 10% of patients from Turkey 
and Egypt. At variance with series from high-income 
countries, another cause potentially present in a large 
portion of patients is hydatidosis. Finally, the presence 
of  membraneous  webs  has  been  reported  in  16%  of 
patients from Turkey. As noted by the authors,
39 this 
prevalence is not as high as in Eastern countries but 
higher  than  in  Western  ones,  ideally  mirroring  the 
position  of  this  area  as  a  bridge  between  East  and 
West. 
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